• Date: March 13, 2018

Founded at the Bellvitge Biomedical Research Institute (IDIBELL), ADmit Therapeutics is aiming to develop a diagnostic test to detect Alzheimer's disease in its very early stages.

It is the fifth spin-off that has resulted from the CaixaImpulse programme, in this case from the Kit for early Alzheimer's detection project from 2015, led by Marta Barrachina. Barrachina is the general director of the new company, and is joined by Ramón Reñé and Jordi Gascón as medical advisory board.

The in vitro diagnostic test developed by ADmit Therapeutics determines whether certain mitochondrial biomarkers are present in the blood. These biomarkers can indicate signs of the disease before the brain starts producing the protein aggregates that characterise Alzheimer's. Early diagnosis would allow those affected to start receiving the treatments available to slow down the progress of the disease, as there are still no treatments to reverse it. The company is seeking private investors as a step towards CE certification.

More news

February 28, 2018

Rare Disease Day celebrates its 10-year anniversary and calls for more research

With the slogan “Show your rare. Show you care”, this year's campaign is dedicated to encouraging research. CaixaImpulse is also playing its part to ensure that research on rare diseases reaches patients.

December 12, 2017

Care Respite uses computer vision to monitor dependent people

In this short interview, Sergio Escalera, CTO of Care Respite, explains how the project took shape, and goes over the time they spent on the programme.

November 17, 2017

Projects implement their valorisation plans

On 10 November, participants pitched their valorisation plans to the CaixaImpulse Valorisation Panel, who will confirm the grants offered to each project. The upcoming months will be devoted to execute the actions included in their respective plans.